I-Corps: In-vitro tool that provides multiparametric information in real-time to determine the efficacy and toxicity of a new drug

这个i-Corps项目的更广泛的影响/商业潜力是改进癌症、心脏病和中风等疾病的更有效药物治疗方法的开发(例如，治疗学或再生医学方法)。该设备提供必要的信息，以便在药物开发的早期阶段确定新产品是否会提供足够的收益或好处。预计这项技术将简化数据处理，同时提供高质量、高成本效益和省时的方法。这种方法将解放出可以投入到新产品开发的物力和人员。这一新系统的优势将缩短新产品进入市场的时间，同时有助于以较少的毒副作用为癌症和其他疾病提供更有效的治疗方法。这一i-Corps项目将提供一种新的体外工具，能够收集多个参数的信息来确定新药的疗效和毒性。这项技术提供了连续和实时收集细胞对(生物)化学和物理刺激反应的数据的手段。与许多传统的检测方法依赖于在实验结束时(终点)收集数据相反，该系统连续收集数据，以减少样本数量提供细胞响应的动态描述。这项技术还将利用对细胞行为数据的持续访问，以开发用于阻抗光谱型测量的数据分析方法。将这一研究工具开发成更自动化的系统，不仅将扩大其在生物制药行业的影响和接受度，还将扩大其在学术、生物医学环境和生物技术行业的影响力和接受度。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is in improving the development of more effective drug treatments (e.g., therapeutics or regenerative medicine approaches) for diseases such as cancer, heart disease, and stroke. This device provides the necessary information to determine, at an early stage in the drug development, if the new product will provide sufficient gain or benefit. It is expected that this technology will simplify data processing while providing a high quality, cost-effective, and time-efficient approach. This approach will free material resources and personnel that can be devoted to the development of new products. The advantages of this new system will reduce the time for new products to reach the marketplace while helping to provide higher efficacy treatments for cancer and other diseases with less toxic side effects.This I-Corps project will provide a new in vitro tool with the capability of gathering information on multiple parameters to determine the efficacy and toxicity of new drugs. This technology provides the means for collecting data on cell responses to (bio)chemical and physical stimuli continuously and in real-time. Contrary to many conventional detection methods that rely on collecting data at the end of the experiment (endpoint), this system collects data continuously, providing a dynamic account of cell responses with a reduced number of samples. This technology will also leverage continuous access to cell behavior data to enable the development of a data analytics approach for impedance spectroscopy-type measurements. The development of this research tool into a more automated system will broaden its impact and acceptance not only in the biopharmaceutical industry but also in academic and biomedical environments and the biotechnology industry.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.